blockers has meant that more patients survive into the later stages of the disease. The clinical challenge ironically then retrogresses to one that involves optimal fl uid balance while preserving renal function. What we may not realise is that the underlying pathophysiology of this "terminal phase" of CHF is poorly understood. The management thereof can be an emotionally and cognitively demanding saga and ultimately there is no consensus amongst the "experts" as to its appropriate care. The cardiorenal syndrome in CHF results from major aberrations in the mutually benefi cial interaction between heart and kidney. It can be seen as a complex interaction between the heart, kidney and vasculature.
DEFINITIONThe cardiorenal syndrome is defi ned as "worsening renal function that The defi nition of worsening renal function remains controversial, with suggestions including a 26.5 umol/l increase in serum creatinine (SCr) above baseline, a rise in SCr above a threshold (221umol/l), a percentage increase from baseline (>25%), or a combination of these factors. (1,2) Whatever the defi nition, clinically this syndrome is not diffi cult to recognise -the challenge is to fi nd effective therapies and management strategies. Seventy percent of patients admitted for acute deteriorating heart failure have decreased renal function and 20-45% will experience an increase in SCr in excess of 26.5 umol/l while in hospital.